دورية أكاديمية
Adoptive T cell therapy for solid tumors: current landscape and future challenges.
| العنوان: | Adoptive T cell therapy for solid tumors: current landscape and future challenges. |
|---|---|
| المؤلفون: | Albarrán V; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., San Román M; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Pozas J; Department of Medical Oncology, The Royal Marsden Hospital, London, United Kingdom., Chamorro J; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Rosero DI; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Guerrero P; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Calvo JC; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., González C; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., García de Quevedo C; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Pérez de Aguado P; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Moreno J; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Cortés A; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain., Soria A; Department of Medical Oncology, Ramon y Cajal University Hospital, Madrid, Spain. |
| المصدر: | Frontiers in immunology [Front Immunol] 2024 Mar 14; Vol. 15, pp. 1352805. Date of Electronic Publication: 2024 Mar 14 (Print Publication: 2024). |
| نوع المنشور: | Journal Article; Review; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Melanoma*, Humans ; Immunotherapy, Adoptive/methods ; Lymphocytes, Tumor-Infiltrating ; T-Lymphocytes ; Cell- and Tissue-Based Therapy ; Tumor Microenvironment |
| مستخلص: | Adoptive cell therapy (ACT) comprises different strategies to enhance the activity of T lymphocytes and other effector cells that orchestrate the antitumor immune response, including chimeric antigen receptor (CAR) T-cell therapy, T-cell receptor (TCR) gene-modified T cells, and therapy with tumor-infiltrating lymphocytes (TILs). The outstanding results of CAR-T cells in some hematologic malignancies have launched the investigation of ACT in patients with refractory solid malignancies. However, certain characteristics of solid tumors, such as their antigenic heterogeneity and immunosuppressive microenvironment, hamper the efficacy of antigen-targeted treatments. Other ACT modalities, such as TIL therapy, have emerged as promising new strategies. TIL therapy has shown safety and promising activity in certain immunogenic cancers, mainly advanced melanoma, with an exciting rationale for its combination with immune checkpoint inhibitors. However, the implementation of TIL therapy in clinical practice is hindered by several biological, logistic, and economic challenges. In this review, we aim to summarize the current knowledge, available clinical results, and potential areas of future research regarding the use of T cell therapy in patients with solid tumors. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2024 Albarrán, San Román, Pozas, Chamorro, Rosero, Guerrero, Calvo, González, García de Quevedo, Pérez de Aguado, Moreno, Cortés and Soria.) |
| التعليقات: | Comment on: N Engl J Med. 2016 Dec 29;375(26):2561-9. (PMID: 28029927) |
| References: | Biomed Pharmacother. 2023 Dec;168:115691. (PMID: 37844355) Mol Ther. 2011 Mar;19(3):620-6. (PMID: 21157437) Mol Cancer. 2023 Jan 30;22(1):20. (PMID: 36717905) Nat Rev Clin Oncol. 2023 Jan;20(1):49-62. (PMID: 36418477) Blood. 2011 Dec 1;118(23):6050-6. (PMID: 21984804) J Clin Oncol. 2021 Aug 20;39(24):2656-2666. (PMID: 33979178) Cancer Sci. 2016 Dec;107(12):1730-1735. (PMID: 27727484) Mol Ther. 2017 May 3;25(5):1248-1258. (PMID: 28366766) JAMA Oncol. 2017 Aug 01;3(8):1094-1101. (PMID: 28426845) J Clin Oncol. 2005 Apr 1;23(10):2346-57. (PMID: 15800326) Clin Cancer Res. 2018 Mar 15;24(6):1277-1286. (PMID: 29138340) Bone Marrow Transplant. 2021 Mar;56(3):552-566. (PMID: 33230186) Mol Cancer. 2019 Aug 20;18(1):125. (PMID: 31429760) Nat Med. 2022 Apr;28(4):724-734. (PMID: 35314843) N Engl J Med. 1988 Dec 22;319(25):1676-80. (PMID: 3264384) Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070) N Engl J Med. 2016 Dec 29;375(26):2561-9. (PMID: 28029927) Adv Exp Med Biol. 2020;1248:61-82. (PMID: 32185707) Front Immunol. 2023 Feb 16;14:1063838. (PMID: 36875091) Nat Med. 2008 Nov;14(11):1264-70. (PMID: 18978797) J Clin Oncol. 2011 Mar 1;29(7):917-24. (PMID: 21282551) Nat Med. 2021 Mar;27(3):419-425. (PMID: 33558725) J Int Med Res. 2021 Jan;49(1):300060520981539. (PMID: 33430667) Clin Cancer Res. 2020 Aug 1;26(15):3979-3989. (PMID: 32371538) Clin Cancer Res. 2015 Mar 1;21(5):1019-27. (PMID: 25538264) Pharmacotherapy. 2017 Mar;37(3):334-345. (PMID: 28079265) J Leukoc Biol. 2020 Oct;108(4):1067-1079. (PMID: 32620049) Cancer Res. 2009 Apr 1;69(7):3077-85. (PMID: 19293190) Cytotherapy. 2020 Oct;22(10):573-580. (PMID: 32527643) Semin Immunol. 2003 Dec;15(6):325-9. (PMID: 15001171) Br J Cancer. 2021 May;124(11):1759-1776. (PMID: 33782566) EBioMedicine. 2022 Mar;77:103941. (PMID: 35301179) Stem Cell Res Ther. 2021 Jan 25;12(1):81. (PMID: 33494834) Nat Med. 2022 Jun;28(6):1189-1198. (PMID: 35534566) Biomark Res. 2022 Apr 25;10(1):24. (PMID: 35468841) Clin Cancer Res. 2014 May 1;20(9):2457-65. (PMID: 24634374) Cancer Discov. 2018 Aug;8(8):944-957. (PMID: 29891538) J Clin Oncol. 2022 Jun 1;40(16):1741-1754. (PMID: 35104158) Oncologist. 2021 Oct;26(10):e1786-e1799. (PMID: 34196068) J Transl Med. 2012 Aug 21;10:169. (PMID: 22909342) Cell Immunol. 2012;273(1):1-9. (PMID: 22230732) Immunooncol Technol. 2022 Jun 18;15:100089. (PMID: 35865122) J Immunother. 2019 May;42(4):126-135. (PMID: 30882547) J Clin Oncol. 2017 Oct 10;35(29):3322-3329. (PMID: 28809608) Blood. 2009 Jul 16;114(3):535-46. (PMID: 19451549) Bioact Mater. 2023 Oct 04;32:124-146. (PMID: 37927901) PLoS One. 2020 Nov 10;15(11):e0242173. (PMID: 33170901) Nature. 2023 Mar;615(7953):687-696. (PMID: 36356599) Oncoimmunology. 2018 May 7;7(7):e1440169. (PMID: 29900044) Sci China Life Sci. 2016 May;59(5):468-79. (PMID: 26968708) J Hematol Oncol. 2020 Jul 2;13(1):86. (PMID: 32616000) Clin Cancer Res. 2023 Sep 1;29(17):3275-3283. (PMID: 37058256) Clin Cancer Res. 2021 Apr 15;27(8):2179-2189. (PMID: 33504555) Nat Immunol. 2022 Oct;23(10):1495-1506. (PMID: 36151395) Nat Med. 2021 Aug;27(8):1410-1418. (PMID: 34385708) Hepatol Int. 2021 Dec;15(6):1402-1412. (PMID: 34850325) J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34607899) J Immunother Cancer. 2022 Jan;10(1):. (PMID: 35086946) Protein Cell. 2018 Oct;9(10):838-847. (PMID: 28710747) Immunity. 2019 Apr 16;50(4):924-940. (PMID: 30995507) Cancers (Basel). 2023 Feb 04;15(4):. (PMID: 36831349) J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66. (PMID: 8028037) N Engl J Med. 2022 Dec 8;387(23):2113-2125. (PMID: 36477031) Clin Cancer Res. 2010 May 1;16(9):2646-55. (PMID: 20406835) Nat Rev Cancer. 2012 Mar 15;12(4):298-306. (PMID: 22419253) J Clin Oncol. 2019 Oct 20;37(30):2759-2768. (PMID: 31408414) J Clin Oncol. 2016 Jul 10;34(20):2389-97. (PMID: 27217459) Clin Cancer Res. 2011 Jul 1;17(13):4550-7. (PMID: 21498393) Biomark Res. 2017 Jun 24;5:22. (PMID: 28652918) Nat Commun. 2020 Jan 15;11(1):291. (PMID: 31941899) Sci Transl Med. 2017 Jul 19;9(399):. (PMID: 28724573) Cell Mol Immunol. 2018 May;15(5):447-457. (PMID: 29375124) Hum Pathol. 2017 Mar;61:130-139. (PMID: 27993576) Clin Cancer Res. 2019 Apr 1;25(7):2096-2108. (PMID: 30573690) Front Oncol. 2022 Aug 16;12:955440. (PMID: 36052255) Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059) Hematol Oncol. 2019 Jun;37 Suppl 1:95-100. (PMID: 31187533) Neuro Oncol. 2018 Oct 9;20(11):1429-1438. (PMID: 29509936) J Clin Oncol. 2015 May 20;33(15):1688-96. (PMID: 25800760) Clin Cancer Res. 2019 Mar 1;25(5):1486-1493. (PMID: 30518633) J Immunother. 2013 Feb;36(2):133-51. (PMID: 23377668) Science. 2006 Oct 6;314(5796):126-9. (PMID: 16946036) Mol Ther. 2017 Sep 6;25(9):2214-2224. (PMID: 28602436) Cancer Immunol Res. 2022 Aug 3;10(8):932-946. (PMID: 35749374) Cancer Res. 2019 Jan 15;79(2):387-396. (PMID: 30482775) Cancer Discov. 2020 May;10(5):702-723. (PMID: 32193224) Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204) N Engl J Med. 2022 Jun 2;386(22):2112-2119. (PMID: 35648703) J Immunother Cancer. 2019 Oct 24;7(1):276. (PMID: 31651363) Blood. 2013 Aug 8;122(6):863-71. (PMID: 23770775) Cancer Immunol Res. 2014 Nov;2(11):1023-33. (PMID: 25367977) Nat Med. 2018 May;24(5):572-579. (PMID: 29662203) Int J Mol Sci. 2019 Mar 14;20(6):. (PMID: 30875739) Lancet Oncol. 2017 Jun;18(6):792-802. (PMID: 28395880) Nature. 2015 Jul 9;523(7559):231-5. (PMID: 25970248) Sci Adv. 2023 Feb 15;9(7):eadf3700. (PMID: 36791198) Science. 2020 Feb 28;367(6481):. (PMID: 32029687) Nature. 2022 Mar;603(7903):934-941. (PMID: 35130560) Cancer Microenviron. 2013 Aug;6(2):123-33. (PMID: 23242673) J Immunother. 2021 Apr 1;44(3):95-105. (PMID: 33284140) Cancer Res. 2014 Dec 15;74(24):7168-74. (PMID: 25477332) Nat Commun. 2021 Oct 14;12(1):6012. (PMID: 34650042) Front Immunol. 2021 Mar 09;12:636568. (PMID: 33767702) Int Immunopharmacol. 2020 Nov;88:106939. (PMID: 33182039) Clin Cancer Res. 2016 Aug 1;22(15):3734-45. (PMID: 27006492) |
| فهرسة مساهمة: | Keywords: T cells; TCR-modified cells; TIL therapy; adoptive cell therapy; car-t; immunotherapy; melanoma |
| تواريخ الأحداث: | Date Created: 20240329 Date Completed: 20240401 Latest Revision: 20240412 |
| رمز التحديث: | 20240412 |
| مُعرف محوري في PubMed: | PMC10972864 |
| DOI: | 10.3389/fimmu.2024.1352805 |
| PMID: | 38550594 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2024.1352805 |